Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $7.7 million.

  • Stoke Therapeutics' Prepaid Assets fell 2124.63% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 2124.63%. This contributed to the annual value of $11.1 million for FY2024, which is 179.33% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Prepaid Assets of $7.7 million as of Q3 2025, which was down 2124.63% from $13.7 million recorded in Q2 2025.
  • Stoke Therapeutics' Prepaid Assets' 5-year high stood at $13.7 million during Q2 2025, with a 5-year trough of $7.7 million in Q3 2025.
  • Over the past 4 years, Stoke Therapeutics' median Prepaid Assets value was $11.0 million (recorded in 2023), while the average stood at $11.2 million.
  • Within the past 5 years, the most significant YoY rise in Stoke Therapeutics' Prepaid Assets was 3237.31% (2025), while the steepest drop was 2124.63% (2025).
  • Quarter analysis of 4 years shows Stoke Therapeutics' Prepaid Assets stood at $10.9 million in 2022, then rose by 3.55% to $11.3 million in 2023, then decreased by 1.79% to $11.1 million in 2024, then crashed by 30.31% to $7.7 million in 2025.
  • Its Prepaid Assets was $7.7 million in Q3 2025, compared to $13.7 million in Q2 2025 and $12.7 million in Q1 2025.